abstract: @entity7 is a chronic @entity2 caused by Actinomyces species which may involve only soft tissue or bone or the two together. @entity6 of maxilla is relatively rare when compared to mandible. These are normal commensals and become pathogens when they gain entry into tissue layers and bone where they establish and maintain an anaerobic environment with extensive @entity3 and @entity1 . This infection spreads contiguously, frequently ignoring tissue planes and surrounding tissues or organ. The portal of entry may be @entity2 , and so forth which may lead to involvement of adjacent structures as pharynx, larynx, tonsils, and paranasal sinuses and has the propensity to damage extensively. Diagnosis is often delayed and is usually based on histopathology as they are cultured in fewer cases. The chronic clinical course without regional @entity4 may be essential in diagnosis. The management of actinomycotic @entity6 is surgical debridement of necrotic tissue combined with antibiotics for 3-6 months. The primary @entity7 arising within the maxilla with contiguous involvement of paranasal sinus with formation of @entity9 is rare. Hence, we present a 50-year-old female @entity0 with @entity8 which presented as @entity9 with suppurative and @entity5 features.

title: Actinomycotic @entity6 Presenting as XXXX : A Rare Case Report.

answer: @entity9


abstract: UNASSIGNED: Several evidences suggest that a small population of cells known as @entity1 stem cells (CSCs) or @entity1 initiating stemlike cells within a @entity1 is capable of @entity1 initiation, maintenance and propagation. Recent publications have supported the existence of CSCs in @entity3 . The pancreatic stem/progenitor cells, which express self-renewal markers, are identified to be present in the peribiliary gland. Based on the CSC hypothesis, mutations can lead to the transformation of stem/progenitor cells or differentiated cells into CSCs. The pancreatic CSCs express a wide array of markers such as @entity4 , @entity9 , ESA, @entity7 , @entity5 , @entity2 , @entity11 / @entity11 and @entity10 . The CSCs are isolated based on surface markers or by other methods such as ALDEFLOUR assay or @entity8 dye exclusion assay. The isolated cells are further characterized by in vitro and in vivo tumorigenic assays. The most important characteristics of CSCs are its ability to self-renew and impart drug resistance towards chemotherapy. Moreover, these distinct cells display alteration of signaling pathways pertaining to CSCs such as Notch, Wnt and @entity6 to maintain the self-renewal process. @entity1 treatment could be attributed to the therapy resistance exhibited by the CSCs. @entity0 and drug resistance in @entity3 is associated with epithelial to mesenchymal transition (EMT). Furthermore, mucins, the high molecular weight proteins are found to be associated with pancreatic CSCs and EMT. Understanding the underlying molecular pathways that aid in the metastatic and drug resistant nature of these distinct cells will aid in targeting these cells. Overall, this review focuses on the various aspects of pancreatic adult/stem progenitors, CSC hypothesis, its markers, pathways, niche, EMT and novel therapeutic drugs used for the elimination of pancreatic CSCs.

title: A concise review on the current understanding of XXXX stem cells.

answer: @entity3


abstract: BACKGROUND: The affective burden of @entity3 has been increasingly recognised. However, subjective reports of distress and its covariates, especially those related to service use, remain under-investigated in @entity0 with @entity2 . METHODS: This study investigated subjective distress and its covariates in a representative sample of 401 outpatients with a confirmed diagnosis of @entity3 in Brazil. @entity1 was assessed using the corresponding domain of a standardised measure of need - the Camberwell Assessment of Need. RESULTS: @entity1 was reported as a need by 165 (41%) @entity0 , being met in 78 (20%) and unmet in 87 (22%). Hierarchical logistic regression showed that the presence of distress as a need was predicted by attendance at psychotherapy (OR=3.49, CI=1.62-7.53), presence of suicidal ideation (OR=2.89, CI=1.75-4.79), non-attendance at psychosocial rehabilitation (OR=2.84, CI=1.31-6.19), and higher psychopathology (OR=1.09, CI=1.06-1.12). An unmet need was predicted by family not accompanying @entity0 to treatment (OR=2.60, CI=1.05-6.44) and higher psychopathology (OR=1.05, CI=1.02-1.09). LIMITATION: The use of a cross-sectional design and a single questionnaire domain to evaluate distress are the main limitations. CONCLUSIONS: Subjective distress is a common unmet need in @entity2 , and can be treated. The main clinical implication is that subjective distress in @entity2 may be impacted on by family engagement and psychosocial interventions.

title: Subjective distress in a representative sample of outpatients with XXXX .

answer: @entity3


abstract: BACKGROUND: The influence of systemic comorbidities on the success of scalp cooling during chemotherapy (CT) is widely unexplored. Comorbidities often require additional medication which itself can occasionally cause @entity7 . This study investigates the influence of selected parameters on the efficacy of scalp cooling for the prevention of CT-induced @entity7 . @entity1 AND METHODS: 226 @entity2 @entity1 were treated with various CT regimens in combination with sensor-controlled scalp cooling. 136 @entity0 @entity1 received (neo)adjuvant therapy, and 76 of these @entity1 received @entity8 and @entity4 (4* EC 3w) followed by @entity6 (12* T w). The following parameters were prospectively investigated: chemotherapy-induced @entity7 , systemic comorbidities and co-medication, @entity5 abuse, hair treatment, menopausal status, and trichologic status. RESULTS: Scalp cooling was successful (no or not visible hair loss; common @entity3 criteria 0-1) in 65% of all @entity1 , in 65% of the 136 @entity0 @entity1 , and in 68% of the 76 @entity1 receiving EC/T. In this subgroup, premenopausal @entity1 (p = 0.009) and those without systemic comorbidities (p = 0.003), without co-medication (p < 0.001) and with high hair density (p = 0.038) showed less hair loss during CT; an effect was also seen for @entity5 abuse (p = 0.023). Hair length and hair treatment had no significant influence. CONCLUSION: Sensor-controlled scalp cooling represents an effective addition to supportive @entity2 therapy. The success of scalp cooling depends on the applied CT regimen. Parameters like menopausal status, systemic comorbidities, medication, @entity5 abuse, and original hair density also influence the outcome of hair loss prevention.

title: The Influence of Various Parameters on the Success of Sensor-Controlled Scalp Cooling in Preventing Chemotherapy-Induced XXXX .

answer: @entity7


abstract: Generation of induced pluripotent stem cells (iPSCs) requires a considerable amount of lipids, such as @entity4 (PA), to meet the needs of subsequent rapid cell division and proliferation. However, it is unclear whether PA, a biosynthetic precursor of lipids, affects reprogramming. By using lentiviral expression of the Yamanaka factors in @entity0 embryonic fibroblasts for reprogramming, we identified that PA is beneficial for the generation of iPS colonies. Inhibiting the generation of cellular PA dramatically decreased the number of iPSCs. Consistently, 400    M PA improved iPSC generation by more than 4- to 5-fold. iPSCs generated in the presence of PA (PA-iPS) expressed pluripotent markers such as @entity3 and @entity5 , differentiated into cells of the three germ layers in vitro, and contributed to chimeric @entity0 when injected into blastocysts. The improved efficiency was primarily due to reduction of apoptosis as sufficient PA increased the accumulation of @entity2 in the inner membrane of the mitochondria, which reduced the release of cytochrome c and, in turn, suppressed apoptosis by inhibiting @entity6 . The relatively higher amount of @entity1 in PA treatment also inhibited apoptosis. In addition, an accompanied sequential change from epithelial-to-mesenchymal transition (EMT) at the initial phase of reprogramming to mesenchymal-to-epithelial transition (MET) was also detected. Our microarray data, which also supported our results, indicated the presence of significant membrane enrichment genes, thus suggesting that PA may function through membrane-anchored proteins. We thus identified a novel type of culture supplement that improves the efficiency of reprogramming and could be valuable for the generation of high-quality iPS cells.

title: XXXX Improves Reprogramming to Pluripotency by Reducing Apoptosis.

answer: @entity4


abstract: INTRODUCTION: @entity3 ( @entity3 ) is a progressive @entity3 over a period of months or years. The major function of the kidneys is the removal of metabolic waste products, electrolytes and water. When this function is impaired, systemic changes, oral complications and alterations in salivary composition may occur. OBJECTIVE: This study aimed to compare the levels of immunological and inflammatory components in the saliva samples from @entity0 that undergo to @entity2 ( @entity2 ), without @entity2 and control. DESIGN: This study evaluated IgA, IgG, @entity5 ( @entity5 ) and @entity4 (NO) in saliva samples from 119 @entity0 , who were divided into the control group (C), @entity3 ( @entity3 ) @entity0 group and @entity3 @entity0 on @entity2 ( @entity2 ) group. IgA and IgG levels were analyzed by ELISA. @entity4 levels were determined indirectly by the @entity6 concentration using Griess reagent; @entity5 by agglutination tests; and total proteins, by Bradford assay. RESULTS: The @entity2 group showed significantly higher levels of IgG, IgA and @entity5 compared with the control and @entity3 groups. The @entity3 group presented the same amounts of IgG, IgA and @entity5 as the C group but significantly higher levels of NO similar to the @entity2 group. CONCLUSION: @entity1 , particularly @entity2 during @entity1 , seems to alter salivary immunological and inflammatory components. Thus, analyzing the levels of IgA, IgG, NO and @entity5 in saliva may be beneficial for monitoring @entity1 .

title: Salivary markers in @entity0 with XXXX .

answer: @entity3


abstract: INTRODUCTION: @entity3 ( @entity3 ) is a progressive @entity3 over a period of months or years. The major function of the kidneys is the removal of metabolic waste products, electrolytes and water. When this function is impaired, systemic changes, oral complications and alterations in salivary composition may occur. OBJECTIVE: This study aimed to compare the levels of immunological and inflammatory components in the saliva samples from @entity0 that undergo to @entity2 ( @entity2 ), without @entity2 and control. DESIGN: This study evaluated IgA, IgG, @entity5 ( @entity5 ) and @entity4 (NO) in saliva samples from 119 @entity0 , who were divided into the control group (C), @entity3 ( @entity3 ) @entity0 group and @entity3 @entity0 on @entity2 ( @entity2 ) group. IgA and IgG levels were analyzed by ELISA. @entity4 levels were determined indirectly by the @entity6 concentration using Griess reagent; @entity5 by agglutination tests; and total proteins, by Bradford assay. RESULTS: The @entity2 group showed significantly higher levels of IgG, IgA and @entity5 compared with the control and @entity3 groups. The @entity3 group presented the same amounts of IgG, IgA and @entity5 as the C group but significantly higher levels of NO similar to the @entity2 group. CONCLUSION: @entity1 , particularly @entity2 during @entity1 , seems to alter salivary immunological and inflammatory components. Thus, analyzing the levels of IgA, IgG, NO and @entity5 in saliva may be beneficial for monitoring @entity1 .

title: Salivary markers in XXXX with @entity3 .

answer: @entity0


abstract: @entity6 ( @entity6 ) with or without epithelioid @entity4 is the most frequent form of @entity1 in @entity2 . Nevertheless, few studies have provided conclusions about its treatment and long-term outcome. We report 22 cases collected over a 20-year period in 9 nephrologic departments of the west of France. We discuss the criteria which permit @entity2 to be distinguished from other causes, particularly of @entity6 drugs. Twenty @entity0 were treated with corticoids. In 18 the result could be evaluated on at least 12 months. In 11 there was a decrease of plasma @entity5 (Pc) and in 8 of these cases this decrease reached 50%. Of the 12 who were followed from 1 to 17 years, 4 obtained a reduction of Pc of at least 50%. These improvements occurred even in @entity0 whose Pc was initially higher than 300 mumol/l. Only 2 @entity0 reached @entity3 and hemodialysis within the observation period, one as early as the first month, the other after 6 years. Five relapses were observed after stopping treatment but 4 responded again favorably upon resumption. Two @entity0 who received no treatment at all nevertheless had stabilization or improvement of their renal function with a follow-up of 5 years for one case. It may be concluded that the long-term prognosis of @entity2 @entity6 can be fairly good but there is no proof that it depends mainly on corticosteroid therapy.

title: [Interstitial XXXX in @entity2 . Effect of corticosteroid therapy and long-term evolution. Retrospective study of 22 cases].

answer: @entity1


abstract: @entity6 ( @entity6 ) with or without epithelioid @entity4 is the most frequent form of @entity1 in @entity2 . Nevertheless, few studies have provided conclusions about its treatment and long-term outcome. We report 22 cases collected over a 20-year period in 9 nephrologic departments of the west of France. We discuss the criteria which permit @entity2 to be distinguished from other causes, particularly of @entity6 drugs. Twenty @entity0 were treated with corticoids. In 18 the result could be evaluated on at least 12 months. In 11 there was a decrease of plasma @entity5 (Pc) and in 8 of these cases this decrease reached 50%. Of the 12 who were followed from 1 to 17 years, 4 obtained a reduction of Pc of at least 50%. These improvements occurred even in @entity0 whose Pc was initially higher than 300 mumol/l. Only 2 @entity0 reached @entity3 and hemodialysis within the observation period, one as early as the first month, the other after 6 years. Five relapses were observed after stopping treatment but 4 responded again favorably upon resumption. Two @entity0 who received no treatment at all nevertheless had stabilization or improvement of their renal function with a follow-up of 5 years for one case. It may be concluded that the long-term prognosis of @entity2 @entity6 can be fairly good but there is no proof that it depends mainly on corticosteroid therapy.

title: [Interstitial @entity1 in XXXX . Effect of corticosteroid therapy and long-term evolution. Retrospective study of 22 cases].

answer: @entity2


abstract: Mortality rates among 838 white female @entity0 @entity1 were examined for relationships to personal characteristics assessed at time of diagnosis. These included weight and body mass index, oral contraceptive use, and prior menstrual and reproductive events. Multivariate analyses were used to determine the importance of these characteristics in predicting @entity3 rates specific for age and extent of disease at time of diagnosis. Weight was associated with poor prognosis among premenopausal @entity1 , but not among postmenopausal @entity1 . Premenopausal @entity1 weighing more than 140 lbs at diagnosis had @entity3 rates 1.7 times those of lighter @entity1 (P = 0.04). This effect was not explained by differences in the distribution of disease stage between the two groups. Body mass index was positively associated with mortality in both premenopausal and postmenopausal @entity1 . In the entire group, the @entity3 rate ratio was 1.4 (P = 0.02) for @entity2 (body mass index greater than 30.4 X 10(-3) lbs/in.2) vs lean @entity1 . Among premenopausal @entity1 , parous @entity1 had higher mortality rates than nulliparous @entity1 ( @entity3 rate ratio = 2.0, P = 0.06). Although the data were sparse, @entity3 rates were higher for @entity1 having a full-term pregnancy within 2 years of diagnosis than for premenopausal @entity1 with earlier pregnancies. Oral contraceptive use, age at menarche, age at first full term birth, and age at menopause were unrelated to mortality.

title: Body size, reproductive factors, and XXXX survival.

answer: @entity0


abstract: UNASSIGNED: Tanning during adolescence increases @entity2 risk. Relatively few studies have examined the association between thinness attitudes and tanning attitudes and behaviors. The purpose of the current study was to examine psychosocial predictors of sunbathing and tanning bed use, specifically thin ideal internalization (TII) and motives for tanning among high school @entity0 . Adolescent @entity0 (N  =  229) completed a 10-minute questionnaire designed to assess sunbathing and indoor tanning, TII and motives to tan (appearance, social and well-being). Hierarchical regression analyses showed that TII, b  =  .05, p  <  .05, appearance motives, b  =  .11, p  <  .01 and well-being motives, b  =  .11, p  <  .01 were all independently positively associated with sunbathing. Social motives were negatively associated with sunbathing, b  =  -.07, p  <  .05. A three-way interaction was found between the three types of motives on indoor tanning, in that appearance and well-being motives interacted to increase indoor tanning levels, especially among those who strongly endorsed social motives for tanning, b  =  .22, p  <  .05. Motives for tanning, specifically those associated with appearance and well-being, can interact to increase tanning bed use. When designing tailored interventions for @entity2 prevention in young @entity0 , researchers should consider tailoring based on motivation. Researchers and healthcare professionals who work with adolescents should attend to tanners who are motivated for both appearance and mood-related reasons, as they may be most at risk for tanning @entity1 and @entity2 .

title: Tan and thin? Associations between attitudes toward thinness, motives to tan and tanning behaviors in adolescent XXXX .

answer: @entity0


abstract: BACKGROUND: Keratoconjunctivitis sicca occurs in 40% to 90% of @entity0 with @entity1 (cGVHD). Ocular symptoms can have profound effects in both the visual function and quality of life of @entity0 with GVHD. We report the impact of prosthetic replacement of the ocular surface ecosystem (PROSE) treatment in @entity0 with cGVHD as a clinical network expands. METHODS: We queried the BostonSight PROSE manufacturing database from January 2002 to December 2011. @entity0 treated for ocular cGVHD were reported by age, gender, year, and network site where the treatment was undertaken. The baseline and six-month follow-up scores of visual function using a standardized validated instrument, the National Eye Institute Visual Function Questionnaire (NEI VFQ-25), were evaluated for a period in 2006 and again in 2010 after network expansion had occurred. RESULTS: A total of 407 @entity0 with a male:female ratio of 226:181, mean age was 51 years with ocular cGVHD underwent PROSE treatment from January 2002 to December 2011. By 2011, 67% of all cases were treated at network clinics. Baseline characteristics of @entity0 treated throughout the network in 2010 were similar to that of 2006 and 2010 cohorts from the main center. There was a significant improvement of 41 points (P<0.001) in composite NEI VFQ score among @entity0 treated across the network in 2010, similar to the improvement of 30 points (P<0.001) seen among the @entity0 treated at the main center in 2010. There was a trend toward lower baseline self-reported general health status (SRGHS) and VFQ scores among @entity0 treated at network clinics, suggesting that expansion of the network allows treatment of sicker @entity0 (lower general health status) or those more severely affected by ocular cGVHD. CONCLUSIONS: PROSE treatment of ocular cGVHD has increased in the last decade with the establishment of BostonSight network clinics across the United States. @entity0 treated at network clinics showed similar levels of baseline visual function and SRGHS, and achieved a similar high level of improvement in visual function as those treated at the main center. @entity0 -reported measures of functional status are useful in evaluating treatment options for @entity0 with cGVHD. PROSE treatment has significant positive impact on the visual function of @entity0 with ocular cGVHD regardless of whether the @entity0 is treated at the main center or at a network site.

title: PROSE Treatment for Ocular XXXX as a Clinical Network Expands.

answer: @entity1


abstract: BACKGROUND: Dietary supplements have a long history of causing adverse effects. @entity3 have not been described with Hydroxycut Gummies. OBJECTIVE: To report a case of @entity3 after prolonged use of a popular dietary supplement, Hydroxycut Gummies. CASE REPORT: An 18-year-old female with no significant past medical history presented with life-threatening @entity3 following about 10 days of use of Hydroxycut Gummies, a legal dietary supplement previously unreported to cause this complication. The @entity0 received external cardioversion due to progressive @entity4 and persistent @entity2 and was initiated on intravenous @entity7 at an outside hospital. Left ventricular ejection fraction was 45% to 50%, and cardiac MRI showed no definite finding of @entity6 , @entity8 , or @entity1 . Beta-blocker therapy was initiated, and there was a progressive reduction in @entity3 burden with an improvement of symptoms over the next few days. Two and a half months after the initial hospitalization, follow-up Holter monitor revealed occasional accelerated idioventricular rhythm events and a significant reduction in, but still occasional, long monomorphic @entity5 events. None of the ingredients listed in this product have been associated with @entity3 in the literature. One phytochemical potentially in the product is @entity9 , which could be the cause of the adverse event. However, there was no other identifiable etiology for the @entity5 , which resolved after the discontinuation of supplement and the addition of beta-blocker therapy. CONCLUSION: Hydroxycut Gummies should be considered a probable cause of this @entity0 's @entity3 given the lack of another etiology and a Naranjo Scale score of 6.

title: XXXX Precipitated by the Use of the Diet Supplement Hydroxycut Gummies.

answer: @entity5


abstract: BACKGROUND: Glycogen depletion and @entity4 have been associated with fatigue and decrement of performance during prolonged exercise. OBJECTIVES: This study investigated the effectiveness of Acacia @entity2 as a post-exercise recovery aid on @entity1 metabolism and subsequent running performance in the heat. @entity0 AND METHODS: Ten subjects participated in this randomized cross-over study. All subjects performed 2 trials. In each trial, all subjects went through a glycogen depletion phase (Run-1), 2-hour rehydration phase and time trial running phase (Run-2). In Run-1, subjects were required to run on a treadmill at 65% VO2max in the heat (31  C, 70% relative humidity) for 60 min. During 2-hour rehydration phase, subjects drank either plain water (PW) or @entity2 ( @entity2 ) with amount equivalent to 150% of body weight loss in 3 boluses (60%, 50% and 40% subsequently) at 0, 30 and 60 min. In Run-2, the longest distance covered in 20 min was recorded for determining running performance. Two-way repeated measured ANOVA and paired t-test were used for analysis. RESULTS: Running distance in Run-2 covered by the subjects in the @entity2 @entity2 trial (3420    350 m) was significantly (P < 0.01) longer compared to plain water PW trial (3120    340 m). In general, plasma @entity1 , serum insulin and osmolality were significantly (P < 0.05) higher in @entity2 compared to PW during the rehydration phase and Run-2. CONCLUSIONS: These findings indicate that rehydration with @entity2 improves running performance and @entity1 metabolism compared to plain water in the heat. Thus, @entity2 can be recommended for rehydration purpose for @entity3 who compete in the heat.

title: Effects of Post-Exercise Honey Drink Ingestion on Blood XXXX and Subsequent Running Performance in the Heat.

answer: @entity1


abstract: UNASSIGNED: Unlike focal or @entity1 , which has a confined range of influence, @entity2 ( @entity2 ) often affects the whole or a larger portion of the brain without obvious, known cause. It is important to understand the underlying network which generates @entity1 activity and through which @entity1 activity propagates. The aim of the present study was to investigate the thalamocortical relationship using non-invasive imaging modalities in a group of @entity2 @entity0 . We specifically investigated the roles of the mediodorsal nuclei in the thalami and the medial frontal cortex in generating and spreading @entity2 activities. We hypothesized that the connectivity between these two structures is key in understanding the generation and propagation of @entity1 activity in brains affected by @entity2 . Using three imaging techniques of EEG, fMRI and EEG-informed fMRI, we identified important players in generation and propagation of generalized spike-and-wave discharges (GSWDs). EEG-informed fMRI suggested multiple regions including the medial frontal area near to the anterior cingulate cortex, mediodorsal nuclei of the thalamus, caudate nucleus among others that related to the GSWDs. The subsequent seed-based fMRI analysis revealed a reciprocal cortical and bi-thalamic functional connection. Through EEG-based Granger Causality analysis using (DTF) and adaptive DTF, within the reciprocal thalamocortical circuitry, thalamus seems to serve as a stronger source in driving cortical activity from initiation to the propagation of a GSWD. Such connectivity change starts before the GSWDs and continues till the end of the slow wave discharge. Thalamus, especially the mediodorsal nuclei, may serve as potential targets for deep brain stimulation to provide more effective treatment options for @entity0 with drug-resistant generalized @entity1 .

title: Thalamocortical relationship in XXXX @entity0 with generalized spike and wave discharges - A multimodal neuroimaging study.

answer: @entity1


abstract: UNASSIGNED: Unlike focal or @entity1 , which has a confined range of influence, @entity2 ( @entity2 ) often affects the whole or a larger portion of the brain without obvious, known cause. It is important to understand the underlying network which generates @entity1 activity and through which @entity1 activity propagates. The aim of the present study was to investigate the thalamocortical relationship using non-invasive imaging modalities in a group of @entity2 @entity0 . We specifically investigated the roles of the mediodorsal nuclei in the thalami and the medial frontal cortex in generating and spreading @entity2 activities. We hypothesized that the connectivity between these two structures is key in understanding the generation and propagation of @entity1 activity in brains affected by @entity2 . Using three imaging techniques of EEG, fMRI and EEG-informed fMRI, we identified important players in generation and propagation of generalized spike-and-wave discharges (GSWDs). EEG-informed fMRI suggested multiple regions including the medial frontal area near to the anterior cingulate cortex, mediodorsal nuclei of the thalamus, caudate nucleus among others that related to the GSWDs. The subsequent seed-based fMRI analysis revealed a reciprocal cortical and bi-thalamic functional connection. Through EEG-based Granger Causality analysis using (DTF) and adaptive DTF, within the reciprocal thalamocortical circuitry, thalamus seems to serve as a stronger source in driving cortical activity from initiation to the propagation of a GSWD. Such connectivity change starts before the GSWDs and continues till the end of the slow wave discharge. Thalamus, especially the mediodorsal nuclei, may serve as potential targets for deep brain stimulation to provide more effective treatment options for @entity0 with drug-resistant generalized @entity1 .

title: Thalamocortical relationship in @entity1 XXXX with generalized spike and wave discharges - A multimodal neuroimaging study.

answer: @entity0


abstract: Three @entity0 with clinically proven @entity8 who later developed @entity3 ( @entity3 )-like features were studied pathologically at necropsy and compared with 42 other cases with @entity3 . The @entity0 were an 18 year old female, a 20 year old male and a 28 year old male. They all had an upper @entity7 as a prodromal symptom and then developed @entity6 on effort, electrocardiographic changes and @entity5 . In case 1, the antibody titers for Coxsackie B2 virus were elevated. In cases 1 and 3, myocardial biopsies revealed a mononuclear cell infiltrate. All 3 died of @entity4 . Histologically, layer-unit depletion of the myocardium (the @entity2 and its sequelae (loss or minimal @entity1 ) are restricted to certain layers), infiltration of mononuclear cells and moderate @entity1 were noted. In case 3, @entity1 and layer-unit depletion of the myocardium were mild. In our 42 @entity3 cases, the mean area of @entity1 was 40% in the @entity1 type, 15% in the nonfibrosis type and 30% in chronic @entity8 . In @entity5 ( @entity5 ), the areas of @entity1 were 21.6%, 21.7% and 13.1% for the 3 cases. Mean cellularity indexes were 3.9% in @entity5 , 5.1% in the @entity1 type of @entity3 , 19.4% in the chronic @entity8 cases and 27% in the nonfibrosis type of @entity3 . With respect to @entity1 and interstitial cellularity, @entity5 most resembles the nonfibrosis type of @entity3 .

title: Three autopsied cases of XXXX . Comparison with @entity3 .

answer: @entity5


abstract: Three @entity0 with clinically proven @entity8 who later developed @entity3 ( @entity3 )-like features were studied pathologically at necropsy and compared with 42 other cases with @entity3 . The @entity0 were an 18 year old female, a 20 year old male and a 28 year old male. They all had an upper @entity7 as a prodromal symptom and then developed @entity6 on effort, electrocardiographic changes and @entity5 . In case 1, the antibody titers for Coxsackie B2 virus were elevated. In cases 1 and 3, myocardial biopsies revealed a mononuclear cell infiltrate. All 3 died of @entity4 . Histologically, layer-unit depletion of the myocardium (the @entity2 and its sequelae (loss or minimal @entity1 ) are restricted to certain layers), infiltration of mononuclear cells and moderate @entity1 were noted. In case 3, @entity1 and layer-unit depletion of the myocardium were mild. In our 42 @entity3 cases, the mean area of @entity1 was 40% in the @entity1 type, 15% in the nonfibrosis type and 30% in chronic @entity8 . In @entity5 ( @entity5 ), the areas of @entity1 were 21.6%, 21.7% and 13.1% for the 3 cases. Mean cellularity indexes were 3.9% in @entity5 , 5.1% in the @entity1 type of @entity3 , 19.4% in the chronic @entity8 cases and 27% in the nonfibrosis type of @entity3 . With respect to @entity1 and interstitial cellularity, @entity5 most resembles the nonfibrosis type of @entity3 .

title: Three autopsied cases of @entity5 . Comparison with XXXX .

answer: @entity3


abstract: UNASSIGNED: : On December 12, 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in combination with @entity9 for the treatment of @entity0 with metastatic @entity8 ( @entity8 ) with disease progression on or after @entity7 -based chemotherapy. @entity0 with @entity5 or anaplastic @entity6 aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab. This approval was based on an improvement in @entity11 ( @entity11 ) with an acceptable @entity3 profile in a randomized, multicenter, double-blinded, placebo-controlled trial of 1,253 @entity0 with metastatic @entity8 previously treated with a @entity7 -based combination therapy. @entity0 were randomized 1:1 to receive either ramucirumab in combination with @entity9 or placebo in combination with @entity9 . The primary endpoint was @entity11 . @entity0 who received ramucirumab in combination with @entity9 had improved @entity11 (hazard ratio [HR]: 0.86; 95% confidence interval [CI]: 0.75, 0.98). Median @entity11 was 10.5 months on the ramucirumab plus @entity9 arm versus 9.1 months on the placebo plus @entity9 arm. The most frequent (>= 30%) adverse reactions in ramucirumab-treated @entity0 were @entity10 , @entity12 , and @entity4 . The most frequent (>= 5%) grade 3 and 4 adverse reactions in the ramucirumab arm were @entity10 , @entity12 , @entity12 , @entity13 , and @entity2 . IMPLICATIONS FOR PRACTICE: This report presents key information on the U.S. Food and Drug Administration approval of ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2, given in combination with @entity9 for the treatment of @entity0 with metastatic @entity8 whose disease has progressed on or after @entity7 -based chemotherapy. This report specifically addresses the issues of safety in @entity0 with @entity14 , effect of treatment in elderly @entity0 , and uncertainties regarding effects in @entity0 with @entity1 harboring @entity5 or anaplastic @entity6 aberrations.

title: U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic XXXX Following Disease Progression On or After @entity7 -Based Chemotherapy.

answer: @entity8


abstract: UNASSIGNED: : On December 12, 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in combination with @entity9 for the treatment of @entity0 with metastatic @entity8 ( @entity8 ) with disease progression on or after @entity7 -based chemotherapy. @entity0 with @entity5 or anaplastic @entity6 aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab. This approval was based on an improvement in @entity11 ( @entity11 ) with an acceptable @entity3 profile in a randomized, multicenter, double-blinded, placebo-controlled trial of 1,253 @entity0 with metastatic @entity8 previously treated with a @entity7 -based combination therapy. @entity0 were randomized 1:1 to receive either ramucirumab in combination with @entity9 or placebo in combination with @entity9 . The primary endpoint was @entity11 . @entity0 who received ramucirumab in combination with @entity9 had improved @entity11 (hazard ratio [HR]: 0.86; 95% confidence interval [CI]: 0.75, 0.98). Median @entity11 was 10.5 months on the ramucirumab plus @entity9 arm versus 9.1 months on the placebo plus @entity9 arm. The most frequent (>= 30%) adverse reactions in ramucirumab-treated @entity0 were @entity10 , @entity12 , and @entity4 . The most frequent (>= 5%) grade 3 and 4 adverse reactions in the ramucirumab arm were @entity10 , @entity12 , @entity12 , @entity13 , and @entity2 . IMPLICATIONS FOR PRACTICE: This report presents key information on the U.S. Food and Drug Administration approval of ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2, given in combination with @entity9 for the treatment of @entity0 with metastatic @entity8 whose disease has progressed on or after @entity7 -based chemotherapy. This report specifically addresses the issues of safety in @entity0 with @entity14 , effect of treatment in elderly @entity0 , and uncertainties regarding effects in @entity0 with @entity1 harboring @entity5 or anaplastic @entity6 aberrations.

title: U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic @entity8 Following Disease Progression On or After XXXX -Based Chemotherapy.

answer: @entity7


abstract: OBJECTIVE: To compare two commercial sleep devices, an accelerometer worn as a wristband (UP) and a smartphone application (MotionX 24/7), against polysomnography (PSG) and actigraphy (Actiwatch2) in a clinical pediatric sample. @entity0 AND METHODS: @entity0 and adolescents (N = 78, 65% male, mean age 8.4  4.0 y) with suspected @entity2 ( @entity2 ), simultaneously wore an actiwatch, a commercial wrist-based device and had a smartphone with a sleep application activated placed near their right shoulder, during their diagnostic PSG. Outcome variables were sleep onset latency (SOL), @entity1 ( @entity1 ), wake after sleep onset (WASO), and @entity1 ( @entity1 ). Paired comparisons were made between PSG, actigraphy, UP, and MotionX 24/7. Epoch-by-epoch comparisons determined sensitivity, specificity, and accuracy between PSG, actigraphy, and UP. Bland-Altman plots determined level of agreement. Differences in bias between @entity2 severity and developmental age were assessed. RESULTS: No differences in mean @entity1 , WASO, or @entity1 between PSG and actigraphy or PSG and UP were found. Actigraphy overestimated SOL (21 min). MotionX 24/7 underestimated SOL (12 min) and WASO (63 min), and overestimated @entity1 (106 min) and @entity1 (17%). UP showed good sensitivity (0.92) and accuracy (0.86) but poor specificity (0.66) when compared to PSG. Bland-Altman plots showed similar levels of bias in both actigraphy and UP. Bias did not differ by @entity2 severity, however was affected by age. CONCLUSIONS: When compared to PSG, UP was analogous to Actiwatch2 and may have some clinical utility in @entity0 with @entity2 . MotionX 24/7 did not accurately reflect sleep or wake and should be used with caution.

title: Comparison of Commercial Wrist-Based and Smartphone Accelerometers, Actigraphy, and PSG in a Clinical Cohort of XXXX and Adolescents.

answer: @entity0


abstract: BACKGROUND: -The clinical course of @entity0 with @entity5 ( @entity5 ) and advanced @entity2 ( @entity2 ) subtended by progressive @entity4 has received limited attention. Our aim was to assess the outcome of @entity2 and impact of treatment options including the @entity3 ( @entity3 ) and @entity1 ( @entity1 ) in @entity5 @entity0 evaluated at two Italian referral centers over 3 decades. METHODS AND RESULTS: -All-cause mortality and a combined end-point including death, @entity1 or appropriate @entity3 shock was assessed in 71 consecutive @entity0 with @entity2 not related to @entity7 (7% of the entire @entity5 cohort) followed for 6.1  6.9 years after development of NYHA class III-IV symptoms. At enrollment, LV ejection fraction was <50% in 55 @entity0 and >50% in 16; all had restrictive LV filling. During follow-up, 35 @entity0 died (49%%; 5-year rate 49%) and 53 met the combined end-point (75%; 5-year rate 62%). Most events occurred in the three years after @entity2 onset (17%/year, compared to only 3%/year subsequently). Appropriate @entity6 occurred in 11 of 34 implanted @entity0 . Of 37 @entity0 evaluated for @entity1 , 14 were transplanted, 10 listed and 13 excluded; two early post- @entity1 deaths occurred in @entity0 with elevated pulmonary vascular resistance. Eleven of the 14 @entity1 @entity0 were alive at 10  8 years. CONCLUSIONS: -In @entity5 , advanced @entity2 not associated with @entity7 portends a severely unfavorable prognosis, particularly in the first three years following onset of symptoms, despite frequently preserved systolic function in about one quarter of the @entity0 . Outcome of @entity1 is favourable but requires early consideration, as the window of opportunity may be short.

title: Clinical Spectrum, Therapeutic Options, and Outcome of Advanced XXXX in @entity5 .

answer: @entity2


abstract: BACKGROUND: -The clinical course of @entity0 with @entity5 ( @entity5 ) and advanced @entity2 ( @entity2 ) subtended by progressive @entity4 has received limited attention. Our aim was to assess the outcome of @entity2 and impact of treatment options including the @entity3 ( @entity3 ) and @entity1 ( @entity1 ) in @entity5 @entity0 evaluated at two Italian referral centers over 3 decades. METHODS AND RESULTS: -All-cause mortality and a combined end-point including death, @entity1 or appropriate @entity3 shock was assessed in 71 consecutive @entity0 with @entity2 not related to @entity7 (7% of the entire @entity5 cohort) followed for 6.1  6.9 years after development of NYHA class III-IV symptoms. At enrollment, LV ejection fraction was <50% in 55 @entity0 and >50% in 16; all had restrictive LV filling. During follow-up, 35 @entity0 died (49%%; 5-year rate 49%) and 53 met the combined end-point (75%; 5-year rate 62%). Most events occurred in the three years after @entity2 onset (17%/year, compared to only 3%/year subsequently). Appropriate @entity6 occurred in 11 of 34 implanted @entity0 . Of 37 @entity0 evaluated for @entity1 , 14 were transplanted, 10 listed and 13 excluded; two early post- @entity1 deaths occurred in @entity0 with elevated pulmonary vascular resistance. Eleven of the 14 @entity1 @entity0 were alive at 10  8 years. CONCLUSIONS: -In @entity5 , advanced @entity2 not associated with @entity7 portends a severely unfavorable prognosis, particularly in the first three years following onset of symptoms, despite frequently preserved systolic function in about one quarter of the @entity0 . Outcome of @entity1 is favourable but requires early consideration, as the window of opportunity may be short.

title: Clinical Spectrum, Therapeutic Options, and Outcome of Advanced @entity2 in XXXX .

answer: @entity5


abstract: BACKGROUND: The aim of this work is to evaluate the utility of multimodal intraoperative monitoring (IOM) during intramedullary @entity3 (IMSCT) surgery in our institution, and to investigate which IOM events are likely to be encountered during critical surgical phases. METHODS: Twenty-five @entity0 who underwent IMSCT surgery with IOM were included in this study. Our multimodal IOM assessment included SSEP, mMEP, and fEMG monitoring. Positive predictive value ( @entity2 ), negative predictive value (NPV), sensitivity, and specificity were assessed 24  h and 1  month after surgery. The IOM events during three main surgical phases were also investigated. For mMEP assessment, two warning criteria (>50  % decrease in mMEP amplitude and all-or-none mMEP amplitude presence) were employed. RESULTS: Long-term outcome prediction was better when the all-or-none criterion was applied than when the >50  % amplitude decrease criterion was applied. Based on the all-or-none criterion, the @entity2 , NPV, sensitivity, and specificity were 60, 100, 100, and 91  %. Frequent IOM events were observed during the three major main surgical phases. Seven (29  %) @entity0 showed SSEP events during opening of the spinal cord. During @entity1 removal, 21 of 25 @entity0 (84  %) had IOM events, and 13 of 18 (72  %) of the fEMG events occurred prior to the mMEP events. CONCLUSIONS: Based on the association of fEMG events with upcoming mMEP events during @entity1 removal, we recommend inclusion of fEMG monitoring in IOM. Multimodal IOM provides useful electrophysiological information during IMSCT surgery, especially during the main surgical phases.

title: Multimodal intraoperative monitoring during intramedullary XXXX surgery.

answer: @entity3


abstract: BACKGROUND: Corticosteroid injections are commonly used in the treatment of @entity3 in adults. This study sought to determine success rates early on and at one year postoperatively of a single corticosteroid injection while identifying prognostic indicators for symptom recurrence and repeat intervention. METHODS: Fifty-four consecutive wrists in forty-nine @entity0 with @entity3 treated with a single @entity2 injection were prospectively enrolled. Demographic data and information on comorbidities were identified with a study-specific questionnaire. The Boston Carpal Tunnel Questionnaire was administered prior to injection. @entity0 returned to clinic at six weeks and were contacted at three, six, nine, and twelve months post-injection to determine symptom and intervention status. Kaplan-Meier analysis and Cox regression modeling were used to estimate recurrence rates and to identify predictors of symptom recurrence and repeat intervention. RESULTS: Fifty-four symptomatic wrists in forty-nine @entity0 with a mean age of fifty-three years were included. Two @entity0 (two wrists) were lost to follow-up. @entity0 reported symptom recurrence in thirty-one wrists at a median duration of 155 days post-injection. Nineteen wrists underwent carpal tunnel release at a median time of 181 days after the injection. No @entity0 underwent a repeat injection. In our study, @entity1 @entity0 were at a 2.6-fold greater risk of reporting recurring symptoms within a one-year follow-up period. Survivorship free from symptom recurrence was 53% at six months and 31% at twelve months; survivorship from repeat intervention was 81% at six months and 66% at twelve months. CONCLUSIONS: A single injection achieved symptom relief in 79% of @entity0 at six weeks; these results were maintained in 31% of @entity0 at twelve months. @entity1 @entity0 were at higher risk of symptom recurrence. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

title: Prognostic Indicators for Recurrent Symptoms After a Single Corticosteroid Injection for XXXX .

answer: @entity3


abstract: BACKGROUND: Proper artificial nutrition for @entity0 who are unable to eat normally is an ongoing, unresolved concern in geriatric medicine and home medical care. Controversy surrounds prognostic differences between parenteral and enteral nutrition, 2 methods for artificial nutrition. OBJECTIVES: Short-term outcomes of parenteral and enteral nutrition for @entity0 who are unable to eat normally were compared and analyzed. DESIGN: Data were acquired from @entity0 selected from a national inpatient database covering 1057 hospitals in Japan. @entity0 had received artificial nutrition between April 2012 and March 2013, were aged >= 20 y, and did not have @entity1 . They were separated into 2 groups: those who received parenteral nutrition and those who received enteral nutrition. We performed one-to-one propensity score matching between the groups. The primary outcome measurements were mortality rates at 30 and 90 d after the start of the procedure. The secondary outcomes were postprocedural complications, @entity2 , and @entity3 . We analyzed survival length of stay after the procedure with the use of a Cox proportional hazards model. RESULTS: There were 3750 @entity0 in the parenteral group and 22,166 @entity0 in the enteral group. Propensity score matching created 2912 pairs in the 2 groups. @entity0 with a similar propensity score (probability of being assigned to the enteral group) calculated from the baseline condition were matched. Mortality rates at 30 and 90 d after start of treatment were 7.6% vs. 5.7% (P = 0.003) and 12.3% vs. 9.9% (P = 0.002) in the parenteral and enteral groups, respectively. In Cox regression analysis, the HR for the enteral group relative to the parenteral group was 0.62 (95% CI: 0.54, 0.71; P < 0.001). The incidences of @entity2 and @entity3 were 11.9% vs. 15.5% (P < 0.001) and 4.4% vs. 3.7% (P = 0.164) for the parenteral and enteral groups, respectively. CONCLUSION: The present analysis showed the better survival rate with enteral compared with parenteral nutrition for adults who were not suffering from @entity1 . This trial was registered at clinicaltrials.gov as NCT02512224.

title: Comparison of short-term mortality and morbidity between parenteral and enteral nutrition for adults without XXXX : a propensity-matched analysis using a national inpatient database.

answer: @entity1


abstract: BACKGROUND: @entity2 is an uncommon condition that could be easily confused with @entity1 . In symptomatic @entity0 , septal "wobble" on echocardiography may be an important sign of constrictive physiology. This study was planned to investigate the effects of @entity4 on septal motion as identified by echocardiography. METHODS: In this retrospective observational study, nine consecutive @entity0 with @entity4 underwent careful echocardiographic analysis of the interventricular septum (IVS) with slow motion 2-dimensional echocardiography and inspiratory manoeuvres. Six @entity0 who had undergone cardiac magnetic resonance imaging underwent similar analysis. Findings were correlated with haemodynamic data in five @entity0 who had undergone cardiac catheterisation studies. RESULTS: In mild cases of @entity4 a single wobble of the IVS was seen during normal respiration. In more moderate cases a double motion of the septum (termed "double wobble") was seen where the septum bowed initially into the left ventricle (LV) cavity in @entity3 then relaxed to the middle only to deviate again into the LV cavity late in @entity3 after atrial contraction. In severe cases, the septum bowed into the LV cavity for the full duration of @entity3 (pan-diastolic motion). We describe how inspiration also helped to characterize the severity of @entity4 especially in mild to moderate cases. CONCLUSION: Echocardiography appears a simple tool to help diagnose @entity4 and grade its severity. Larger studies are needed to confirm whether the type of wobble motions helps to grade the severity of @entity2 .

title: A Potential Echocardiographic Classification for XXXX Based on Analysis of Abnormal Septal Motion.

answer: @entity2


abstract: UNASSIGNED: Aims. Inhibitors of the MET pathway hold promise in the treatment for metastatic @entity2 . Assessment of predictive biomarkers may be necessary for appropriate @entity0 selection. Understanding MET expression in metastases and the correlation to the primary site is important, as distant tissue is not always available. Methods and Results. MET immunofluorescence was performed using automated quantitative analysis and a tissue microarray containing matched nephrectomy and distant metastatic sites from 34 @entity0 with @entity3 . Correlations between MET expressions in matched primary and metastatic sites and the extent of heterogeneity were calculated. The mean expression of MET was not significantly different between primary @entity1 when compared to metastases (P = 0.1). MET expression weakly correlated between primary and matched metastatic sites (R = 0.5) and a number of cases exhibited very high levels of discordance between these @entity1 . Heterogeneity within nephrectomy specimens compared to the paired metastatic tissues was not significantly different (P = 0.39). Conclusions. We found that MET expression is not significantly different in primary @entity1 than metastatic sites and only weakly correlates between matched sites. Moderate concordance of MET expression and significant expression heterogeneity may be a barrier to the development of predictive biomarkers using MET targeting agents.

title: MET Expression in Primary and Metastatic XXXX : Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.

answer: @entity3


abstract: Both @entity10 and @entity9 + exert a @entity2 action on the twitch amplitude elicited by nerve stimulations more rapidly than that by muscle stimulation. @entity9 + was relatively more potent than @entity10 in the nerve @entity2 action but was weaker on the muscle. @entity10 induced a rapid phase and a slow phase of @entity6 in the diaphragm, while @entity9 + induced only a slow one. The biphasic @entity6 induced by @entity10 could be inhibited by repetitive washout of the diaphragm with low @entity1 (10(-3) mM) Krebs and also by treatment with @entity3 to close T-tubule, while the slow @entity6 induced by @entity9 + was little affected by @entity3 treatment. None of denervation, @entity8 and @entity5 inhibited the @entity6 induced by @entity10 and @entity9 +, indicating that the @entity6 was induced by a direct action on the muscle. @entity10 , but not @entity9 +, rapidly caused a decrease of the membrane potential, decreased the amplitude and prolonged the duration of the muscle action potential. @entity10 also initially decreased and then increased 45 @entity1 uptake of the diaphragm, but @entity9 + had no effect, except a prolonged incubation at a high concentration. The action of @entity10 could be antagonized by @entity7 , and @entity9 + was more susceptible than @entity10 to the antagonistic action of @entity7 . Both @entity10 and @entity9 + did not change the @entity4 content of the diaphragm. All of these findings indicate that the monovalent organic @entity9 +, with a higher lipophilicity, possesses a higher affinity to the nerve while the divalent cationic @entity10 exerted more effects than @entity9 + on the sarcolemma of the @entity0 diaphragm.

title: Differential effects of mercurial and methylmercurial ions on the phrenic nerve and diaphragm of the XXXX .

answer: @entity0


abstract: The primary audience of poison prevention programs is the parent(s) of @entity0 less than 6 years of age. Literature review reveals few references assessing other caretakers as risk factors in childhood @entity1 . The frequency and severity of calls to the poison center by nonparental caretakers was studied. A total of 4,205 @entity1 cases involving @entity0 under 6 years of age were analyzed. In 11.9% of the cases the caretaker at the time of exposure was someone other than the parents and the site of the exposure was other than the @entity0 's home. Of the 3,702 cases where the exposure occurred while the @entity0 was supervised by the parents in their home, 90.2% were treated in the home and 72.4% required dilution only. Grandparents represented 39.6% of caretakers other than the parents. In these cases 44.6% required treatment beyond dilution, indicating more serious exposures in this group. Ingestion of cardiovascular drugs occurred in 12.3% of calls from grandparents as opposed to 0.7% of calls initiated by parents. Poisoning exposures involving @entity0 under six years of age, where the caretaker is other than the parents, and the site is other than the @entity0 's home, are often more serious. Poison prevention information programs are needed to reduce the risk factors among this group.

title: Accidental childhood XXXX : influence of the type of caretaker on etiology and risk.

answer: @entity1


abstract: BACKGROUND: In severely symptomatic @entity0 with @entity3 ( @entity3 ) and mild @entity4 , @entity1 may play an important role in MV displacement into the left ventricular (LV) outflow tract. Therefore, isolated myectomy may not relieve outflow obstruction and symptoms, and MV replacement is often the surgical alternative. OBJECTIVES: This study sought to assess the clinical and hemodynamic results of cutting thickened secondary MV chordae combined with a shallow septal muscular resection in severely symptomatic @entity0 with obstructive @entity3 and mild @entity4 . METHODS: Clinical features were compared before surgery and at most recent clinical evaluation in 39 consecutive @entity0 with obstructive @entity3 . RESULTS: Over a 23    2 months follow-up, New York Heart Association functional class decreased from 2.9    0.5 pre-operatively to 1.1    1.1 post-operatively (p  < 0.001), with no @entity0 in class III at most recent evaluation. The resting outflow gradient decreased from 82    43 mm Hg to 9    5 mm  Hg (p  < 0.001) and septal thickness decreased from 17    1 mm to 14    2 mm (p  < 0.001). No @entity0 had MV prolapse or flail and 1 had residual moderate-to-severe MV regurgitation at most recent evaluation. MV geometry before and after surgery was compared with that of 25  consecutive @entity0 with similar clinical profile and septal thickness that underwent isolated myectomy. After adjustment for differences in pre-operative values between the groups, the post-operative anterior MV leaflet-annulus ratio was 17% greater and tenting area 24% smaller in @entity0 with chordal cutting, indicating that MV apparatus had moved to a more normal posterior position within the LV cavity, preventing MV systolic displacement into the outflow tract and outflow obstruction. CONCLUSIONS: This procedure relieves @entity2 , abolishes LV outflow gradient, and avoids MV replacement in @entity0 with obstructive @entity3 and mild septal thickness.

title: Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive XXXX With Mild @entity4 .

answer: @entity3


abstract: BACKGROUND: In severely symptomatic @entity0 with @entity3 ( @entity3 ) and mild @entity4 , @entity1 may play an important role in MV displacement into the left ventricular (LV) outflow tract. Therefore, isolated myectomy may not relieve outflow obstruction and symptoms, and MV replacement is often the surgical alternative. OBJECTIVES: This study sought to assess the clinical and hemodynamic results of cutting thickened secondary MV chordae combined with a shallow septal muscular resection in severely symptomatic @entity0 with obstructive @entity3 and mild @entity4 . METHODS: Clinical features were compared before surgery and at most recent clinical evaluation in 39 consecutive @entity0 with obstructive @entity3 . RESULTS: Over a 23    2 months follow-up, New York Heart Association functional class decreased from 2.9    0.5 pre-operatively to 1.1    1.1 post-operatively (p  < 0.001), with no @entity0 in class III at most recent evaluation. The resting outflow gradient decreased from 82    43 mm Hg to 9    5 mm  Hg (p  < 0.001) and septal thickness decreased from 17    1 mm to 14    2 mm (p  < 0.001). No @entity0 had MV prolapse or flail and 1 had residual moderate-to-severe MV regurgitation at most recent evaluation. MV geometry before and after surgery was compared with that of 25  consecutive @entity0 with similar clinical profile and septal thickness that underwent isolated myectomy. After adjustment for differences in pre-operative values between the groups, the post-operative anterior MV leaflet-annulus ratio was 17% greater and tenting area 24% smaller in @entity0 with chordal cutting, indicating that MV apparatus had moved to a more normal posterior position within the LV cavity, preventing MV systolic displacement into the outflow tract and outflow obstruction. CONCLUSIONS: This procedure relieves @entity2 , abolishes LV outflow gradient, and avoids MV replacement in @entity0 with obstructive @entity3 and mild septal thickness.

title: Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive @entity3 With Mild XXXX .

answer: @entity4


abstract: PURPOSE: To compare the use of @entity2 ( @entity3 ) or bevacizumab ( @entity4 ) as adjunctive in the needling revision of failed trabeculectomy blebs. METHODS: @entity1 @entity0 with failed trabeculectomy were included. @entity5 were excluded. All procedures were performed by the same surgeon at the operating room under peribulbar blockade. Rate of success, intraocular pressure (IOP), and number of antiglaucoma drugs in use were compared before and after the procedures. The IOP was measured postoperatively at days 1, 30, 90, and 180. Absolute success was defined as IOP  <=18 mm Hg, without any complication or use of any antiglaucomatous drugs. Qualified success was the same criteria, but with the use of any antiglaucomatous drugs. RESULTS: Twenty-nine eyes of 29 @entity0 were included: 15 eyes with @entity3 and 14 eyes with @entity4 . There was no statistical difference in the IOP reduction between the groups ( @entity3 32.6    16.1% vs @entity4 30.1    12.0%, p = 0.6).  The @entity4 group showed similar reduction in the number of antiglaucoma drugs compared to the @entity3 group (p = 0.6). Absolute success was found in 28.5% of the @entity4 group and in 6.6% of @entity0 with @entity3 . Qualified success was found in 64.3% and 73.4%, respectively, both limited to 180 days. CONCLUSIONS: In this selected and limited group of @entity0 , bevacizumab can be considered as an alternative to @entity3 in the needling revision of failed trabeculectomy. Studies with a larger number of @entity0 and longer follow-up are needed to confirm the hypothesis suggested here.

title: Prospective study comparing XXXX or bevacizumab as adjuvant in trabeculectomy revision by needling.

answer: @entity2


abstract: We aimed to estimate the total number of serious @entity6 occurring yearly in Belgium. The number of @entity5 was retrieved from the National Reference Center for @entity11 . Populations at risk and @entity6 frequencies in these populations were used to estimate incidence or prevalence of other @entity6 . The Belgian population consists of 11.10 million @entity0 . @entity10 is rare. In all, 15 of the 1227 newly diagnosed @entity8 / @entity9 cases presented with @entity14 jirovecii @entity2 . This accounts for   14% of total @entity13 cases (n  =  120). The incidence of candidaemia is estimated as 5/100  000 resulting in 555 cases and 213 deaths. A total number of 675 @entity1 cases and >= 169 deaths attributed to this infection were calculated. Chronic @entity3 is estimated to be prevalent in 662 cases. Allergic @entity3 cases were estimated to be 23  119 applying a 2.5% and 15% rate in adult @entity7 and cystic @entity4 @entity0 respectively. Severe @entity7 with fungal sensitisation cases was estimated to be 30  402. There were 174  760 @entity0 with recurrent @entity12 assuming a 6% rate in @entity0 aged between 15 and 50. Approximately 233  000 @entity0 of the Belgian population (2.1%) are estimated to suffer from a @entity6 on a yearly basis.

title: Burden of serious XXXX in Belgium.

answer: @entity6


abstract: We report a rare case of advanced @entity4 which showed complete resolution of multiple @entity1 following nephrectomy, partial metastatectomy and interferon therapy. A 55-year-old male @entity0 underwent right nephrectomy for the @entity4 with @entity1 to the right lung and the left femur. In 45 days from the nephrectomy, @entity1 to the right humerus was discovered. Immediately after this, the @entity0 suffered occlusive ileus. Laparotomy revealed multiple @entity5 , and a temporary partial jejunotomy was performed for the detectable lesions proved to be @entity1 later. After this operation the @entity3 revealed regression. Then, the @entity0 was treated with daily intramuscular administration of @entity0 lymphoblastic interferon (3 X 10(6) units). In consequence, the @entity3 showed complete resolution in two months and the humeral lesion in five months. The left femur which remained osteolytic was replaced by an artificial bone, and revealed no @entity2 cells histologically. No evidence of metastatic lesion has been found with following intestinal examinations. More than a year has passed since the detection of disease and complete response has persisted for three months under the interferon therapy.

title: [A case of complete resolution of multiple @entity1 of advanced XXXX following partial jejunotomy in intestinal @entity1 and interferon therapy].

answer: @entity4


abstract: We report a rare case of advanced @entity4 which showed complete resolution of multiple @entity1 following nephrectomy, partial metastatectomy and interferon therapy. A 55-year-old male @entity0 underwent right nephrectomy for the @entity4 with @entity1 to the right lung and the left femur. In 45 days from the nephrectomy, @entity1 to the right humerus was discovered. Immediately after this, the @entity0 suffered occlusive ileus. Laparotomy revealed multiple @entity5 , and a temporary partial jejunotomy was performed for the detectable lesions proved to be @entity1 later. After this operation the @entity3 revealed regression. Then, the @entity0 was treated with daily intramuscular administration of @entity0 lymphoblastic interferon (3 X 10(6) units). In consequence, the @entity3 showed complete resolution in two months and the humeral lesion in five months. The left femur which remained osteolytic was replaced by an artificial bone, and revealed no @entity2 cells histologically. No evidence of metastatic lesion has been found with following intestinal examinations. More than a year has passed since the detection of disease and complete response has persisted for three months under the interferon therapy.

title: [A case of complete resolution of multiple XXXX of advanced @entity4 following partial jejunotomy in intestinal @entity1 and interferon therapy].

answer: @entity1


abstract: We report a rare case of advanced @entity4 which showed complete resolution of multiple @entity1 following nephrectomy, partial metastatectomy and interferon therapy. A 55-year-old male @entity0 underwent right nephrectomy for the @entity4 with @entity1 to the right lung and the left femur. In 45 days from the nephrectomy, @entity1 to the right humerus was discovered. Immediately after this, the @entity0 suffered occlusive ileus. Laparotomy revealed multiple @entity5 , and a temporary partial jejunotomy was performed for the detectable lesions proved to be @entity1 later. After this operation the @entity3 revealed regression. Then, the @entity0 was treated with daily intramuscular administration of @entity0 lymphoblastic interferon (3 X 10(6) units). In consequence, the @entity3 showed complete resolution in two months and the humeral lesion in five months. The left femur which remained osteolytic was replaced by an artificial bone, and revealed no @entity2 cells histologically. No evidence of metastatic lesion has been found with following intestinal examinations. More than a year has passed since the detection of disease and complete response has persisted for three months under the interferon therapy.

title: [A case of complete resolution of multiple @entity1 of advanced @entity4 following partial jejunotomy in intestinal XXXX and interferon therapy].

answer: @entity1


abstract: BACKGROUND: Blunt @entity4 (BTAIs) remain a leading cause of @entity2 after blunt @entity1 . In severe @entity1 , thoracic endovascular aortic repair (TEVAR) has provided a less invasive alternative to conventional open repair. OBJECTIVE: To report the TEVAR-related complications and uncertainties in @entity0 who presented with traumatic @entity5 (grade III BTAI). METHODS: From April 2004 to February 2012, 55 @entity0 (42 male, mean age 34.7 years) with severe BTAI were treated with stent grafts. Computed tomography (CT) was used to diagnose the @entity1 , and follow-up scans were planned at 6 and 12 months. We report the complications and the technical uncertainties related to the procedure. RESULTS: Successful sealing of the injury sites was achieved in all @entity0 , either with a thoracic stent graft (53/55) or infrarenal @entity3 extender cuffs (2/55). During hospitalisation, 13 @entity0 died after TEVAR (mean 14 days). Procedure-related complications included left common carotid artery coverage (1/55), ischaemic left leg (1/55) and graft collapse (1/55). The procedurerelated uncertainties included excessive graft oversizing (15/55), poor graft apposition to the inner curve of the aorta (19/55) and left subclavian artery coverage (24/55). CONCLUSION: Stent grafts appear safe and effective in treating @entity5 caused by BTAI. However, they are likely to be associated with long-term complications and monitoring strategies of >30 years may be necessary.

title: Lessons learned from the endovascular management of blunt XXXX : A single-centre experience.

answer: @entity4


abstract: PURPOSE: Approximately 10-15% of @entity0 @entity1 treated by breast conserving surgery (BCS) and adjuvant radiotherapy (RT) will develop ipsilateral @entity0 recurrence (IBTR). International guidelines suggest total mastectomy as treatment of choice for IBTR following lumpectomy and RT. Nevertheless, there is evidence that second BCS might be equally sufficient. @entity1 AND METHODS: @entity1 with IBTR diagnosed between 1990 and 2014 after BCS and RT were included (n  =  170). 34.1% @entity1 underwent secondary BCS, whereas 65.9% were treated by mastectomy. We determined predictive factors for @entity3 ( @entity3 ), disease free survival (DFS), and @entity2 ( @entity2 ) comparing these two groups. RESULTS: Median follow-up after primary IBTR was 49 months (59 months for @entity1 still alive at time of analysis). Five-year IBTR-free rate after secondary BCS was 77.6% (SD      6.1%) and 75.0% (SD      4.5%) for @entity1 after mastectomy. Five-year DFS was 57.3% (SD      8.2%), and 61.9% (SD      5.5%), five-year @entity2 was 84.7% (SD      5.8%), and 72.6% (SD      5.1%), respectively. Prior adjuvant systemic therapy, muscular invasion, and skin infiltration were independent significant risk factors for a shorter @entity3 . Additionally, lymphovascular infiltration (LVI) in the IBTR increased the risk for a shorter DFS. LVI, muscular invasion, and skin infiltration were identified as independent significant risk factors for a shorter @entity2 . CONCLUSION: No significant difference in local control, DFS, and @entity2 was seen between IBTR @entity1 treated either by secondary BCS or mastectomy. Our data suggest that secondary BCS for IBTR @entity1 after initial BCS and RT is feasible in selected @entity1 .

title: Surgical management of ipsilateral XXXX recurrence.

answer: @entity0


abstract: BACKGROUND: @entity7 is a rare presentation for @entity0 in the @entity5 ( @entity5 ), primarily affecting immunocompromised @entity0 . Multiple forms of @entity4 are present, and with poor prognosis, @entity5 diagnosis and treatment of this deadly condition are necessary. OBJECTIVE OF REVIEW: The aim of this review is to provide an overview of the presentations and forms of @entity7 , diagnosis, and treatment of this @entity3 . DISCUSSION: This review provides background on the fungi causing @entity7 , which are prevalent in nature. The article discusses the risk factors for @entity4 with @entity7 , as normal hosts are able to clear the disease, but immunocompromised and @entity1 @entity0 are at risk for organism inoculation and spread. The fungi are angioinvasive and cause @entity2 . This article describes the various forms of the disease: rhino-orbital-cerebral, pulmonary, central nervous system, gastrointestinal, renal, disseminated, and cutaneous. Finally, this review evaluates diagnosis, treatment, and prognosis. CONCLUSION: Emergency department diagnosis and treatment are necessary in @entity0 with @entity4 with @entity7 . Physicians should be suspicious of this disease in immunocompromised and @entity1 @entity0 . Treatment requires antifungal agents such as @entity6 and surgical debridement. Prognosis is poor.

title: XXXX : what do emergency physicians need to know?

answer: @entity7


abstract: UNASSIGNED: @entity4 features @entity2 . To date, there has been no curative therapy for this @entity2 . No systemic report on a long-term effect of @entity1 ( @entity1 ) for Morquio A has been described. We conducted @entity1 for 4 cases with Morquio A (age at @entity1 : 4-15years, mean 10.5years) and followed them at least 10years (range 11-28years; mean 19years). Current age ranged between 25 and 36years of age (mean 29.5years). All cases had a successful full engraftment of allogeneic bone marrow transplantation without serious GVHD. Transplanted bone marrow derived from HLA-identical siblings (three cases) or HLA-identical unrelated donor. The levels of the enzyme activity in the recipient's lymphocytes reached the levels of donors' enzyme activities within two years after @entity1 . For the successive over 10years post-BMT, @entity3 activity in lymphocytes was maintained at the same level as the donors. Except one case who had osteotomy in both legs one year later post BMT, other three cases had no orthopedic surgical intervention. All cases remained ambulatory, and three of them could walk over 400m. Activity of daily living (ADL) in @entity0 with @entity1 was better than untreated @entity0 . The @entity0 who underwent @entity1 at four years of age showed the best ADL score. In conclusion, the long-term study of @entity1 has demonstrated therapeutic effect in amelioration of progression of the disease in respiratory function, ADL, and biochemical findings, suggesting that @entity1 is a therapeutic option for @entity0 with Morquio A.

title: Hematopoietic stem cell transplantation for XXXX .

answer: @entity4


abstract: BACKGROUND: @entity6 is a chronic disease caused mainly by @entity5 species that belong to Viannia subgenus. It affects upper respiratory airways and may lead to @entity1 , @entity4 , and even @entity2 in severe cases. Diagnosis is a challenge because clinical and histopathologic changes are easily confused with other diseases, and conventional methods for parasite identification and culture have a low sensitivity. Molecular methods have been used in the last two decades. In 2007, we published a validation study using internal transcript spacers and kinetoplast DNA as molecular targets with satisfactory results. In this research, we tested miniexon gene as the target. METHODS: Mucosal tissue samples from 60 Colombian @entity0 with clinical signs of @entity6 were included. A composite reference standard defined 30 cases and 30 controls. Two blind observers performed @entity0 classification and test application independently. Miniexon gene amplification generated: 226-230 bp fragment for subgenus Viannia; 308 bp fragment for L. amazonensis; 340 bp fragment for L. mexicana; and 418 bp fragment for @entity5 -chagasi. RESULTS: Polymerase chain reaction (PCR) sensitivity for fresh samples was 87.5% (95% confidence interval [CI] 72.2-100), specificity, 95% (95% CI 83.0-100), and positive likelihood ratio was 17.5 (95% CI 2.58-118.93), similar to results obtained with @entity3 -embedded samples. Agreement between observers was 96% (kappa = 0.912; 95% CI 0.815-1.000) for both subgenus Viannia and @entity5 . CONCLUSIONS: We consider PCR-miniexon as a diagnostic method of first choice for @entity6 due to its excellent diagnostic performance and its ability to discriminate between @entity5 and Viannia subgenera as well as between species belonging to @entity5 subgenus.

title: Polymerase chain reaction-miniexon: a promising diagnostic method for XXXX .

answer: @entity6


abstract: UNASSIGNED: Quality improvement depends on data collection and audit of clinical services to inform clinical improvements. Various steps in the care of the @entity1 can be used to audit a service but need defined audit standards. A @entity1 foot service should have risk stratification system in place that should compare to the population based figures of 76% having low risk feet, 17% moderate risk and 7% being at high risk of @entity2 . Resources can then be directed towards those with high risk feet. Prevalence of foot @entity2 needs audited. Community based studies give an audit standard of around 2%, with 2 to 9% having had an @entity2 at some stage in the past. Amputation rates should be easier to measure and the best results are reported to be around 1.5-3 per 1,000 @entity0 with @entity1 . This is a useful benchmark figure and the rate has been shown to decrease by approximately a third over the last fifteen years in some centres. Ulceration rates and @entity2 rates are the ultimate outcome audit measure as they are always undesirable, whilst occasionally for defined individuals an amputation can be a good outcome. In addition to clinical outcomes, processes of care can be audited such as provision of clinical services, time from new @entity2 to be seen by health-care professional, in- @entity0 foot care or use of antibiotics. Measurement of clinical services can be a challenge in the @entity1 , but it is essential if clinical services and @entity0 outcomes are to be improved. This article is protected by copyright. All rights reserved.

title: When and how to audit a XXXX service.

answer: @entity1


abstract: Excessive neutrophil stimulation and reactive @entity1 species (ROS) production are involved in numerous @entity0 or @entity4 pathologies. The modulation of the neutrophil @entity3 oxidase (NOX) has a great therapeutic potential since this enzyme produces @entity2 anion whose most of the other ROS derive. The measurement of NOX activity by cell-free systems is often used to test potential inhibitors of the enzyme. A major drawback of this technique is the possible interferences between inhibitors and the probe, ferricytochrome c, used to measure the activity. We designed the "EquiNox2", a new pharmacological tool, to determine the direct interaction of potential inhibitors with @entity4 phagocytic NOX and their effect on the enzyme activity or assembly. This method consists in binding the membrane fractions of neutrophils containing flavocytochrome b558 or the entire complex, reconstituted in vitro from membrane and cytosolic fractions of PMNs, onto the wells of a microplate followed by incubation with potential inhibitors or drugs. After incubation, the excess of the drug is simply eliminated or washed prior measuring the activity of the reconstituted complex. This latter step avoid the risk of interference between the inhibitor and the revelation solution and can distinguish if inhibitors, strongly bound or not, could interfere with the assembly of the enzymatic complex or with its activity. The EquiNox2 was validated using @entity5 and Gp91ds-tat, two well-known inhibitors largely described for @entity0 @entity3 oxidase. The present technique was used to study and understand better the effect of @entity6 and its water-soluble derivative, NDS27, on the assembly and activity of NOX. We demonstrated that @entity6 and NDS27 can strongly bind to the enzyme and prevents its assembly making these molecules good candidates for the treatment of @entity4 or @entity0 pathologies implying an excessive activation of neutrophils.

title: EquiNox2: A new method to measure XXXX oxidase activity and to study effect of inhibitors and their interactions with the enzyme.

answer: @entity3


abstract: BACKGROUND: Radiofrequency ablation (RFA) can be used to treat renal masses in @entity0 where surgery is preferably avoided. As @entity1 size and location can affect ablation results, procedural planning needs to identify these factors to limit treatment to a single session and increase ablation success. PURPOSE: To identify factors that may affect the primary efficacy of complete @entity2 ablation with radiofrequency after a single session. MATERIAL AND METHODS: Percutaneous RFA (using an impedance based system) was performed using computed tomography (CT) guidance. Fifty-two @entity2 (in 44 @entity0 ) were retrospectively studied (median follow-up, 7 months). Data collection included @entity0 demographics, @entity1 data (modified Renal Nephrometry Score, histopathological diagnosis), RFA treatment data (electrode placement), and follow-up results ( @entity1 relapse). Data were analyzed through generalized estimating equations. RESULTS: Primary efficacy rate was 83%. Predictors for complete ablation were optimal electrode placement (P   =   0.002, OR   =   16.67) and increasing distance to the collecting system (P   =   0.02, OR   =   1.18). @entity1 size was not a predictor for complete ablation (median size, 24   mm; P   =   0.069, OR   =   0.47), but all @entity1  <=2   cm were completely ablated. All @entity1 and @entity4 were completely ablated in a single session; the most common incompletely ablated @entity1 type was @entity3 (6 of 9). CONCLUSION: Optimal electrode placement and a long distance from the collecting system are associated with an increased primary efficacy of @entity2 RFA. These variables need to be considered to increase primary ablation success. Further studies are needed to evaluate the effect of RFA on histopathologically different @entity2 .

title: Predictive factors for complete XXXX ablation using RFA.

answer: @entity2


abstract: BACKGROUND: Only few previous case reports have been found focusing on the imaging findings of adult @entity3 ( @entity3 ). PURPOSE: To characterize multislice computed tomography (MSCT), magnetic resonance imaging (MRI) characteristics, and follow-up results of adult @entity3 . MATERIAL AND METHODS: Sixteen @entity0 with @entity3 were studied retrospectively. MSCT and MRI were undertaken to investigate the @entity1 characteristics. RESULTS: @entity1 (mean diameter, 13.1        4.5   cm) exhibited an expansible appearance and disrupted the reniform contour (16/16), cystic components (16/16), curvilinear calcification (1/16), poorly marginated (2/16), @entity2 (16/16), displacement of renal pelvis or calyx (13/16), and had lymph node or distal metastases (5/16). Attenuation of @entity3 was less or equal compared to renal parenchyma on unenhanced CT (P   >   0.05), while @entity1 enhancement after administration of a contrast agent was lower than that of normal renal parenchyma (P   <   0.05). @entity3 was isointense on T1-weighted (T1W) imaging, isointense or hypointense on T2-weighted (T2W) imaging. @entity1 enhancement was less than normal renal cortex in all phases (P   <   0.05). The number of @entity1 stages (grades I, II, III, and IV) was two, three, six, and five cases, respectively. Follow-up time was in the range of 19-123 months; six @entity0 died within 3 years, six @entity0 died within 5 years after the initial diagnosis, with the remaining @entity0 still alive. CONCLUSION: Adult @entity3 tends to be a large @entity1 , isointense or hypointense on T2W imaging with enhancement less than normal renal parenchyma in all phases. The long-term follow-up results demonstrated the poor prognosis of the @entity1 .

title: CT and MRI imaging features and long-term follow-up of adult XXXX .

answer: @entity3


abstract: UNASSIGNED: Kinins are important vasoactive peptides, but the role of the B1 receptor subtype in the vascular control is poorly understood. This study analyzed the @entity3 (NO) release, @entity6 ( @entity2 ) uptake and the expression of the cationic @entity5 transporter (CAT) -1 in endothelial cells obtained from B1 receptor knockout (B1-/-) and @entity1 ( @entity1 ) @entity0 . NO production was assessed through a fluorescent dye in living cells stimulated with @entity4 . @entity2 uptake was determined indirectly in the culture medium by HPLC, in the presence or absence of the @entity9 blocker @entity7 ( @entity8 ). @entity9 mRNA levels and protein expression were determined by qPCR and western blot, respectively. NO release was significantly reduced in B1-/- when compared to @entity1 cells. This result was accompanied by a decreased rate in the @entity2 uptake by B1-/- cells. Incubation with @entity8 impaired the @entity2 uptake in @entity1 , but had no effect in B1-/- cells. Protein expression and mRNA levels for @entity9 were reduced in B1-/- in comparison to @entity1 cells. These findings suggest an important role of the endothelial B1 receptor in the vascular control by interfering with @entity9 expression, @entity2 uptake and NO release.

title: XXXX Transport and @entity3 Production in Kinin Receptor B1-/- Endothelial Cells.

answer: @entity6


abstract: UNASSIGNED: Kinins are important vasoactive peptides, but the role of the B1 receptor subtype in the vascular control is poorly understood. This study analyzed the @entity3 (NO) release, @entity6 ( @entity2 ) uptake and the expression of the cationic @entity5 transporter (CAT) -1 in endothelial cells obtained from B1 receptor knockout (B1-/-) and @entity1 ( @entity1 ) @entity0 . NO production was assessed through a fluorescent dye in living cells stimulated with @entity4 . @entity2 uptake was determined indirectly in the culture medium by HPLC, in the presence or absence of the @entity9 blocker @entity7 ( @entity8 ). @entity9 mRNA levels and protein expression were determined by qPCR and western blot, respectively. NO release was significantly reduced in B1-/- when compared to @entity1 cells. This result was accompanied by a decreased rate in the @entity2 uptake by B1-/- cells. Incubation with @entity8 impaired the @entity2 uptake in @entity1 , but had no effect in B1-/- cells. Protein expression and mRNA levels for @entity9 were reduced in B1-/- in comparison to @entity1 cells. These findings suggest an important role of the endothelial B1 receptor in the vascular control by interfering with @entity9 expression, @entity2 uptake and NO release.

title: @entity6 Transport and XXXX Production in Kinin Receptor B1-/- Endothelial Cells.

answer: @entity3


abstract: BACKGROUND: Chronic @entity0 are frequent users of healthcare services and are prone to hospital admissions. In Valencia (Spain) the Valcronic programme aims to manage chronic @entity0 through different levels of telemonitoring and telecare. This paper examines the impact of the Valcronic programme on self-perceived HRQOL in a one-year period and on perceptions of satisfaction and usefulness in a sample of older adults with @entity1 . METHODS: The sample (n=74) was randomly selected from Valcronic users and was stratified considering different variables. HRQOL was assessed using the EQ-5D questionnaire at two points in time: before the beginning of the Valcronic programme and after a one-year follow-up. Satisfaction and usefulness were evaluated one year after users' inclusion. RESULTS: The whole sample experienced improvement, although not significant, of its HRQOL; @entity0 over 75 showed impairment. @entity0 with at least one problem in the EQ-5D dimensions decreased after one year (82.43% vs. 74.32%). Users' perceptions of satisfaction and usefulness were highly positive. CONCLUSIONS: Our sample benefited from the Valcronic programme, experiencing an improvement in their HRQOL, a decreased use of health resources or high satisfaction levels. IMPLICATIONS: Further adjustments are needed to address a comprehensive response to the needs of the global population of reference.

title: Impact of a primary-based telemonitoring programme in HRQOL, satisfaction and usefulness in a sample of older adults with XXXX in Valencia (Spain).

answer: @entity1


abstract: @entity6 ( @entity6 ) is a @entity1 which has been recognized as a separate entity due to its close geographic clustering of affected @entity0 . The study aimed at evaluating the clinical and immunological features of @entity6 with chronic symptoms of @entity7 , @entity5 and pauciarticular @entity2 . Six @entity0 with @entity6 and erosive @entity2 who developed an increase of serum IgM rheumatoid factor (RF) which correlated with the inflammatory activity of the disease are described in detail. Besides raised IgG antibody titers to @entity4 (B. burgd.) antigen measured by ELISA technique, circulating immune complexes, antinuclear antibodies (ANA) and RF measured by laser nephelometric immunoassay were detected. Increased ANA and RF antibody rates suggest that @entity6 may closely be linked with transient @entity3 . Thus, in some cases, B. burgd. antigens might be able to produce a strong polyclonal B-cell stimulation, hence leading to an unspecific @entity3 . But the question remains if transient unspecific @entity3 actually take part in the pathogenesis of @entity6 .

title: Acquired transient XXXX in Lyme @entity2 : correlation between rheumatoid factor and disease activity.

answer: @entity3


abstract: @entity6 ( @entity6 ) is a @entity1 which has been recognized as a separate entity due to its close geographic clustering of affected @entity0 . The study aimed at evaluating the clinical and immunological features of @entity6 with chronic symptoms of @entity7 , @entity5 and pauciarticular @entity2 . Six @entity0 with @entity6 and erosive @entity2 who developed an increase of serum IgM rheumatoid factor (RF) which correlated with the inflammatory activity of the disease are described in detail. Besides raised IgG antibody titers to @entity4 (B. burgd.) antigen measured by ELISA technique, circulating immune complexes, antinuclear antibodies (ANA) and RF measured by laser nephelometric immunoassay were detected. Increased ANA and RF antibody rates suggest that @entity6 may closely be linked with transient @entity3 . Thus, in some cases, B. burgd. antigens might be able to produce a strong polyclonal B-cell stimulation, hence leading to an unspecific @entity3 . But the question remains if transient unspecific @entity3 actually take part in the pathogenesis of @entity6 .

title: Acquired transient @entity3 in Lyme XXXX : correlation between rheumatoid factor and disease activity.

answer: @entity2


abstract: BACKGROUND: This study evaluates the effectiveness of a training programme for improving the diagnostic and treatment quality of the most complex service offered by @entity2 ( @entity2 ) providers, paediatric @entity1 . The study further assesses whether any quality improvements were sustained over the following 12  months. METHODS: The study took place in 13 townships in central Myanmar between January 2011 and October 2012. A total of 251 community health workers were recruited and trained in the provision of paediatric and adult @entity1 diagnosis and treatment; 197 were surveyed in all three rounds: baseline, 6 and 12  months. Townships were selected based on a lack of alterative sources of medical care, averaging 20  km from government or private professional health care treatment facilities. Seventy percent of recruits were assistant nurse midwives or had other basic health training; the rest had no health training experience. Recruits were evaluated on their ability to properly diagnosis and treat a simulated 5-year-old @entity0 using a previously validated method known as Observed Simulated @entity0 . A trained observer scored @entity2 providers on a scale of 1-100, based on WHO and Myanmar MOH established best practices. During a pilot test, 20 established private physicians operating in @entity1 -endemic areas of Myanmar scored an average of 70/100. RESULTS: Average quality scores of newly recruited @entity2 providers prior to training (baseline) were 12/100. Six months after training, average quality scores were 48/100. This increase was statistically significant (p  <  0.001). At 12  months after training, providers were retested and average quality scores were 45/100 (R3-R1, p  <  0.001). CONCLUSION: The @entity2 training programme was able to improve the quality of paediatric @entity1 care significantly, and to maintain that improvement over time. Quality of care remains lower than that of trained physicians; however, @entity2 providers operate in rural areas where no trained physicians operate. More research is needed to establish acceptable and achievable levels of quality for community health workers in rural communities, especially when there are no other care options.

title: Improving the quality of paediatric XXXX diagnosis and treatment by rural providers in Myanmar: an evaluation of a training and support intervention.

answer: @entity1


abstract: Between January 1978 and June 1985, 44 @entity0 underwent cystectomy for clinically diagnosed superficial @entity3 . Operative mortality was 13.6%. Early and late complications were observed in 34 and 55% @entity0 , respectively. Clinical understaging was seen in 23%, and stage reduction in 18% of the @entity0 . Clinical staging was correct in 59% of the @entity0 . The mean follow-up was 40 months (range, 24-84 months). Five @entity0 presented local recurrence (13%) of the @entity2 and 10 @entity0 showed distant @entity1 (26%). Urethral and upper urinary tract recurrences were observed in 7 and 4 @entity0 , respectively. Fourteen @entity0 (39%) died of @entity2 after a mean follow-up of 24 months. The actuarial 5-year survival was achieved by 77% of the @entity0 with PTo-PTa-PTis and by 67% of the @entity0 with @entity4 (p, not significant).

title: Place of cystectomy in superficial XXXX .

answer: @entity3


abstract: UNASSIGNED: Studies looking at the relationship of the @entity5 to suicidal behavior and its risk factors, such as @entity1 , @entity3 , and @entity0 , report inconsistent results. These studies also do not always differentiate between subjects who go on to attempt suicide, suicidal subjects who never attempted suicide, and non-suicidal subjects with @entity0 . In this study, we examined @entity2 responses to an experimental stressor, the Trier Social Stress Test (TSST), in 208 offspring of parents with @entity4 . Offspring suicide attempters showed lower total @entity2 output (b=-0.47, 95% CI (-0.83, -0.11), p=0.01) compared with offspring with suicide-related behavior (SRB) but never attempted, non-suicidal offspring, and a healthy control group. The result remained significant even after controlling for sex, age, race, ethnicity, site, socio-economic status, and hour of the day when the TSST was conducted. Suicide attempters also showed lower baseline @entity2 before the TSST (b=-0.45, 95% CI (-0.74, -0.17), p=0.002). However, there were no significant differences between the groups on @entity2 reactivity to stress (b=4.5, 95% CI (-12.9, 22), p=0.61). Although subjects with suicide attempt and SRB have similar clinical and psychosocial characteristics, this is the first study to differentiate them biologically on @entity5 indices. Blunted @entity5 activity may increase risk for suicide attempt among individuals with psychopathology by reducing their ability to respond adaptively to ongoing stressors. These results may help better identify subjects at high risk for suicidal behavior for targeted prevention and intervention efforts.Neuropsychopharmacology advance online publication, 4 November 2015; doi:10.1038/npp.2015.309.

title: Blunted XXXX Activity in Suicide Attempters Compared to those at High Risk for Suicidal Behavior.

answer: @entity5


abstract: Recent reports suggest a role for @entity4 in the pathogenesis of primary @entity2 and left ventricular (LV) @entity5 . In this study, we have induced @entity8 by oral feeding of @entity7 at increasing dosages (150-450 micrograms/kg b.wt.) over a 5-week period. The effects of @entity6 on @entity1 , blood and myocardial @entity4 concentrations were assessed. Water-fed @entity0 and formerly @entity6 recovered animals served as controls. @entity7 caused a significant @entity8 : @entity6 @entity0 2.19 +/- 0.16*; controls 1.65 +/- 0.13 g/kg b.wt. (mean +/- SD; *P less than 0.05). An almost complete regression of @entity8 occurred in the recovery group (1.66 +/- 0.20 g/kg b.wt.) 3 weeks after cessation of thyroid hormone application. @entity7 -treated animals showed a significant increase of @entity4 blood levels ( @entity7 @entity0 : 2108 +/- 781*, recovery: 1132 +/- 726, controls: 705 +/- 480 ng/ml; *P less than 0.05). The concentrations of @entity4 in left ventricular myocardium were increased after thyroid hormone application, whereas the highest levels were found in the recovery group ( @entity7 @entity0 : 139.1 +/- 30.4, recovery: 167.2 +/- 43.1, controls: 68.9 +/- 27.9 mg/ml homogenate). @entity4 -containing cells in the left ventricular myocardium were stained immunohistochemically. They were localized perivascularly and were assumed to represent tissue mast cells. In experimental @entity6 the @entity4 levels in blood and heart are increased possibly indicating an interaction of both hormones in @entity7 -induced @entity3 .

title: Influence of experimental @entity6 on blood and myocardial XXXX in @entity0 .

answer: @entity4


abstract: Recent reports suggest a role for @entity4 in the pathogenesis of primary @entity2 and left ventricular (LV) @entity5 . In this study, we have induced @entity8 by oral feeding of @entity7 at increasing dosages (150-450 micrograms/kg b.wt.) over a 5-week period. The effects of @entity6 on @entity1 , blood and myocardial @entity4 concentrations were assessed. Water-fed @entity0 and formerly @entity6 recovered animals served as controls. @entity7 caused a significant @entity8 : @entity6 @entity0 2.19 +/- 0.16*; controls 1.65 +/- 0.13 g/kg b.wt. (mean +/- SD; *P less than 0.05). An almost complete regression of @entity8 occurred in the recovery group (1.66 +/- 0.20 g/kg b.wt.) 3 weeks after cessation of thyroid hormone application. @entity7 -treated animals showed a significant increase of @entity4 blood levels ( @entity7 @entity0 : 2108 +/- 781*, recovery: 1132 +/- 726, controls: 705 +/- 480 ng/ml; *P less than 0.05). The concentrations of @entity4 in left ventricular myocardium were increased after thyroid hormone application, whereas the highest levels were found in the recovery group ( @entity7 @entity0 : 139.1 +/- 30.4, recovery: 167.2 +/- 43.1, controls: 68.9 +/- 27.9 mg/ml homogenate). @entity4 -containing cells in the left ventricular myocardium were stained immunohistochemically. They were localized perivascularly and were assumed to represent tissue mast cells. In experimental @entity6 the @entity4 levels in blood and heart are increased possibly indicating an interaction of both hormones in @entity7 -induced @entity3 .

title: Influence of experimental XXXX on blood and myocardial @entity4 in @entity0 .

answer: @entity6


abstract: Recent reports suggest a role for @entity4 in the pathogenesis of primary @entity2 and left ventricular (LV) @entity5 . In this study, we have induced @entity8 by oral feeding of @entity7 at increasing dosages (150-450 micrograms/kg b.wt.) over a 5-week period. The effects of @entity6 on @entity1 , blood and myocardial @entity4 concentrations were assessed. Water-fed @entity0 and formerly @entity6 recovered animals served as controls. @entity7 caused a significant @entity8 : @entity6 @entity0 2.19 +/- 0.16*; controls 1.65 +/- 0.13 g/kg b.wt. (mean +/- SD; *P less than 0.05). An almost complete regression of @entity8 occurred in the recovery group (1.66 +/- 0.20 g/kg b.wt.) 3 weeks after cessation of thyroid hormone application. @entity7 -treated animals showed a significant increase of @entity4 blood levels ( @entity7 @entity0 : 2108 +/- 781*, recovery: 1132 +/- 726, controls: 705 +/- 480 ng/ml; *P less than 0.05). The concentrations of @entity4 in left ventricular myocardium were increased after thyroid hormone application, whereas the highest levels were found in the recovery group ( @entity7 @entity0 : 139.1 +/- 30.4, recovery: 167.2 +/- 43.1, controls: 68.9 +/- 27.9 mg/ml homogenate). @entity4 -containing cells in the left ventricular myocardium were stained immunohistochemically. They were localized perivascularly and were assumed to represent tissue mast cells. In experimental @entity6 the @entity4 levels in blood and heart are increased possibly indicating an interaction of both hormones in @entity7 -induced @entity3 .

title: Influence of experimental @entity6 on blood and myocardial @entity4 in XXXX .

answer: @entity0